Kornimate/medical-research-clean huggingface dataset:
comparison of the tibiofemoral rotational alignment after mobile and fixed bearing total knee arthroplasty

Conditions: Osteoarthritis

Summary: the anatomic landmark for the anteroposterior (ap) axis of the proximal tibia and its variability was investigated in this study in order to determine whether a certain landmark could be employed as a reference axis for the proximal tibia after rotating platform mobile bearing (rp-mb) and fixed bearing (fb) total knee arthroplasties (tkas).

reference of tibial ap axis for implanting tibial component in total knee arthroplasty have not been concluded. this study can suggest appropriate method for alingning the tibial component to accurate tibial ap axis.

Eligibility criteria:
inclusion criteria: * primary osteoarthritis exclusion criteria: * infection * inflammatory arthritis * reoperation * severe deformity

Keywords: arthroplasty replacement knee rotational alignment
combined intracameral lidocaine for manual small incision cataract surgery under topical anesthesia

Conditions: Cataract

Summary: the purpose of this study is to determine whether intraocular lidocaine increases patient comfort during the different stages of msics while under topical anesthesia.


Eligibility criteria:
inclusion criteria: * both men and women * cataract density grade iii-v according to the emery-little system classification system * patients need to do manual small incision cataract surgery exclusion criteria: * legal guardian(s) is/are not present for permission * any patient with a known sensitivity or allergy to lidocaine or the "caine" family of medicines. * patients with altered levels of pain perceptions

Keywords: topical analgesia flacc pain scale intracameral lignocaine anesthetics physiological effects of drugs lidocaine
efficacy study of intranasal insulin to treat tobacco abstinence syndrome

Conditions: Tobacco Abstinence Syndrome

Summary: this study will evaluate safety and efficacy of intranasal insulin in abstinent smokers. groups' (placebo vs. insulin) cognitive function and stress response will be compared.


Eligibility criteria:
inclusion criteria: * smokers (\>10 cig/day) for the past 1 year * normosmic olfactory function exclusion criteria: * previous/current use of insulin * current diagnostic and statistical manual-iv-revised (dsm-iv-r) axis i disorder * current pregnancy (or lactation) * lifetime history of endocrine disease * excessive alcohol use (\>25 standard units of alcohol/week) * current use of illicit drugs * current use of a smoking cessation aid (nrt, chantix or wellbutrin), or a psychotropic agent * local infections, inflammation, structural abnormalities, or other nasal pathology * current use of any medications administered intranasally, including intranasal steroids
retrospective study of ramucirumab and paclitaxel in gastric or gastroesophageal junction adenocarcinoma

Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma

Summary: this is a retrospective, multicenter, non-interventional study for the evaluation of real-world efficacy and safety of ramucirumab plus paclitaxel in gastric or gastroesophageal junction adenocarcinoma as part of the establishment of hospital medical record collection system to evaluate drug effectiveness by health insurance review \& assessment service (hira). the medical records in approximately 1400 patients with locally-advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, who have received ramucirumab plus paclitaxel combination therapy will be collected.

ramucirumab plus paclitaxel combination therapy has shown a survival benefit in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. however, the real-world efficacy and safety of ramucirumab plus paclitaxel combination therapy in korea have only been evaluated once outside of controlled clinical trials. therefore, this large multicenter retrospective analysis was designed to evaluate the real-world efficacy and safety of ramucirumab plus paclitaxel under the korea national health insurance system. the medical records in approximately 1400 patients with locally-advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, who have received ramucirumab plus paclitaxel combination therapy between may 2018 and december 2018 will be collected. eligibility criteria included age ≥ 19 years, histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma, locally advanced unresectable or metastatic disease, and previous first-line systemic therapy including fluoropyrimidine and platinum. efficacy was evaluated by overall survival, progression free survival, time to progression, objective response rate, disease control rate, and duration of response. safety was evaluated by hematologic or non-non hematologic toxicities and adverse events of special interest with ramucirumab plus paclitaxel combination therapy.

Eligibility criteria:
inclusion criteria: 1. age ≥19 years at the time of study registration 2. histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma 3. locally advanced unresectable or metastatic disease 4. patients who have received previous palliative first-line systemic therapy including fluoropyrimidine and platinum for advanced gastric or gastroesophageal junction adenocarcinoma 5. patients who have received ramucirumab plus paclitaxel combination therapy between may 2018 and december 2018 under the korea national health insurance system exclusion criteria: 1. patients who have received ramucirumab plus paclitaxel combination therapy outside of the korea national health insurance system 2. patients who have received ramucirumab monotherapy
evaluation of diabetes control and effect on transmission and development of tuberculosis

Conditions: Latent Tuberculosis; Diabetes Mellitus

Summary: clinical test (essay) randomized to evaluate the toxicity adherence and efficiency of the chemoprophylaxis of tuberculosis (tb) in subjects with diabetes mellitus (dm) and latent tb. (600 subjects followed(continued) by 15 months). 3rd stage. patients with dm and tb will be included to determine if the strict control of the dm achieved in clinics of the first level of attention improves clinical manifestations of tb, the result of treatment, the frequency of relapses, the mortality and the transmission to contacts. elispot will be used to measure tb development and the time for the bacteriological negativization and biochemical parameters as well as tuberculin skin test (tst), quantiferon, in contacts. (160 patients 600 contacts followed(continued) for 12 months). additional there will be evaluated the socioeconomic impact of both diseases and his(her) control. 1er year: transverse study and recruitment years 2 and 3 participants' follow-ups in clinical tests(essays).


Eligibility criteria:
inclusion criteria: * positive hiv tst tuberculin exclusion criteria: * previous tb treatment hepatic failure aids

Keywords: treatment latent infection tuberculosis interferon gamma
early fall risk detection and fall prevention among inpatients with delirium

Conditions: Delirium in Old Age; Delirium Superimposed on Dementia; Fall; Bed Falls

Summary: during delirium patients are at risk of severe harm due to unattended bed-exits resulting in falls. this research intends to explore how effective alarming contact mats (caremat®) in comparison to contactless bed-exit alarming devices (qumea®) are to reduce the risk of unattended bed-exits and falls.

delirium is a neuropsychiatric disorder with a sudden and reversible decline in attention and cognition due to a medical condition.8 delirium is associated with emotional distress for patients, their relatives and medical staff.3-5 during delirium, patients are at risk of severe harm due to unattended bed-exits and subsequent falls.6, 7 as worldwide strategy, sitters are used for the prevention of harm in patients with delirium. however, evidence of the effectiveness of sitters is scant.9 a newly designed specialised acute care unit for older patients with delirium, the felix platter delirium unit (delirunit), strives to overcome the aforementioned shortcomings. on the delirunit there are no physical barriers such as bed rails to prevent patients from bed-exits. floor beds minimize injuries when patients leave their beds unattended. specialised nurses and nursing aides care for this vulnerable patient group. sitters are banned. as an alternative to sitters, nurses are informed about patients' intended bed-exit by electronic alarming contact mats at the bedside or in front of beds (caremat®) or by a novel contactless radar-based bed-exit monitoring system (qumea®). up until now, evidence for the effectiveness of technical devices for fall risk prevention is low. this research intends to explore how effective contact mats (caremat®) or contactless bed-exit alarming devices (qumea®) are in fall risk detection and fall prevention.

Eligibility criteria:
inclusion criteria: admission at or transferal to delirunit. during covid pandemic, patients will be enrolled into the study after the second negative covid swab (pcr). exclusion criteria: patients who have been sectioned and must be treated in a facility, whether they agree or not (under the mental health act) (fürsorgliche unterbringung). no proxy consent available due to language barriers; missing legal proxy in case of lacking family network

Keywords: bed-exit bed-exit warning device contact mat 3-d-radar device
a multi-modal remote monitoring platform for frontotemporal lobar degeneration (ftld) syndromes

Conditions: PSP; CBD; Progressive Supranuclear Palsy; FTD; Corticobasal Degeneration; Frontotemporal Dementia; Frontotemporal Lobar Degeneration

Summary: the primary objective of this study is to enroll an observational cohort of approximately 60 patients with psp over the course of 24 months using a multicenter study design and to follow each of them for 12 months. the secondary objective of this study is to develop a robust solution for multi-modal remote monitoring of motor symptoms and function in psp that can be applied to other frontotemporal lobar degeneration (ftld) syndromes.

the goal of this project is to develop a robust multi-modal platform for remote monitoring of motor symptoms and cognitive function in ftld syndromes using wearable sensors and mobile health technology to assess speech, motor, and cognitive functions. the solution will be validated in progressive supranuclear palsy (psp) by collecting longitudinal data from 60 psp individuals with psp. enrollment will take place over a period of 24 months, though each participant will only be followed for 12 months for data collection. the participants will consist of adult volunteers from two leading curepsp centers of care located at the atypical parkinsonism center at johns hopkins hospital in baltimore, md and massachusetts general hospital (mgh) in boston, ma.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of possible or probable psp as defined by the 2017 mds criteria * fluent in reading and speaking english and capable of providing informed consent based on the principal investigator's judgement * able to walk 10 feet unassisted at the time of initial enrollment * must have a caregiver or study partner who is willing and able to assist with all study-related procedures exclusion criteria: * any neurological, medical, or psychiatric condition that would preclude participation in study activities based on the investigator's judgment. * a history of frequent falls defined as more than 5 falls per month, or who require a walker to ambulate safely at baseline will not be eligible to participate in the study.
influences of sugammadex on postoperative progress in patients with myasthenia gravis undergoing video-assisted thoracoscopic thymectomy: retrospective study

Conditions: Myasthenia Gravis

Summary: "several case reports have described the use of rocuronium and sugammadex in patients with myasthenia gravis (mg). however, reports regarding the effects of sugammadex compared with that of acetylcholinesterase inhibitors (acheis) on perioperative outcomes of video-assisted thoracoscopic surgery (vats)-thymectomy in patients with mg are still lacking. thus, the investigators will investigate the effects of sugammadex compared to acheis on the postoperative recovery in patients with mg who underwent vats-thymectomy. this retrospective study include patients with mg, aged\> 18 years who received sugammadex or pyridostigmine-glycopyrrolate or neostigmine-glycopyrrolate after vats-thymectomy between november 2007 and december 2020. inverse probability of treatment weighting (iptw) adjustment will be performed to balance the baseline characteristics between the two groups. the primary outcome is the length of postoperative hospital stay, and the secondary outcomes are the incidence of postoperative mortality and postoperative complications, as well as postoperative extubation and reintubation rates in the operating room after vats-thymectomy; the outcomes are compared between the two groups. "


Eligibility criteria:
inclusion criteria: * patients underwent vats-thymectomy between november 2007 and december 2020 exclusion criteria: * patients who was not diagnosed with myasthenia gravis * age ≤ 18 * patients for which no reversal agent was used
validation of an ai-assisted pancreatic eus system for training improvement: a prospective, multi-center, randomized trial

Conditions: Pancreatic Diseases

Summary: the goal of this clinical trial is to verify the auxiliary role of the artificial intelligence (ai) system in pancreatic endoscopic ultrasound (eus) scans. the main questions it aims to answer are as follows: 1. a comparison of the image recognition accuracy between the ai system and eus endoscopists. 2. whether the ai system can improve the quality of scans for eus endoscopists. participants will conduct eus scanning with or without the assistance of the ai system.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years old, \<80 years old 2.patients who need endoscopic ultrasonography of pancreas; 3. agree to participate in this study and sign the informed consent form. exclusion criteria: subjects who meet any of the following criteria cannot be selected for this trial: first. the patient's physical condition does not meet the requirements of conventional endoscopic ultrasonography: poor physical condition, including hemoglobin ≤8.0g/dl, severe cardiopulmonary insufficiency, etc. anesthesia assessment failed pregnancy or breastfeeding in the acute stage of chemical and corrosive injury, it is very easy to cause perforation recent acute coronary syndrome or clinically unstable ischemic heart attack heart disease patients with right-to-left shunt, patients with severe pulmonary hypertension (pulmonary artery pressure\> 90mmhg), patients with uncontrolled systemic hypertension and patients with adult respiratory distress syndrome. second. disagree to participate in this study. third. there are other problems that do not meet the requirements of this research or that affect the results of the research: pancreatic disease has undergone surgery or radiotherapy and chemotherapy beforehand; mental illness, drug addiction, inability to express themselves or other diseases that may affect follow-up.
probiotics in prevention of common cold

Conditions: Viral Infections of the Upper Respiratory Tract

Summary: the objective of this study is to assess the benefit and tolerability of a probiotic product in subjects with increased susceptibility to common cold.


Eligibility criteria:
inclusion criteria: * males and females * age 18-70 years * increased risk for common cold (at least 4 episodes within 12 months) * commitment to adhere to former diet and physical activity * commitment not to use any products that may influence the study outcome (e.g. immune suppressants/immune stimulants, including paramedication such as e.g. echinacea, analgesics/anti-rheumatics, anti-phlogistics, antitussives/expectorants, influenza remedies, mouth or throat therapeutics, decongestants, antibiotics, anti-histaminergic drugs, probiotics) during the study (except for rescue medication, see 7.5) * women of child-bearing potential have to agree to use appropriate birth control methods written consent of the subject to participate is a prerequisite for study participation. exclusion criteria: * acute / chronic upper / lower airways disease * chronic cough of any origin * any allergic reaction that may influence the study outcome (e.g. acute/chronic rhinitis) * history of nasal reconstructive surgery * presence of nasal ulcers or nasal polyps * severe nasal septum deviation or other condition that could cause nasal obstruction * congenital or acquired immunodeficiency disease (e.g. hiv infection) * bechterew's disease * body temperature above 37.5°c * suspected swine flu or influenza * vaccination with a vaccine containing an adjuvant within 3 months prior to study start and during the study * vaccination with a vaccine not containing an adjuvant within 6 weeks prior to study start and during the study * stomach/gastrointestinal diseases * serious organ or systemic diseases * sleep disorder * psychiatric disorders * known sensitivity to the ingredients of the investigational product * regular intake of products that may influence the study outcome (e.g. immune suppressants/immune stimulants, including paramedication such as e.g. echinacea, analgesics/anti-rheumatics, anti-phlogistics, antitussives/expectorants, influenza remedies, mouth or throat therapeutics, decongestants, antibiotics, anti-histaminergic drugs, probiotics) within the last 4 weeks prior to study start * habitual usage of nasal drops/spray * pregnancy or nursing * alcohol / drug abuse * simultaneous participation in another clinical trial or participation in a clinical trial within the last 30 days * insufficient compliance
post extubation delirium and end-tidal sevoflurane concentration

Conditions: Delirium on Emergence

Summary: the purpose of this study is to determine whether the incidence of emergence delirium will be reduced when end-tidal concentration of sevoflurane decreases.

sevoflurane induction and maintenance were selected. intubation was performed after lidocaine spray on vocal cord. after that, an effective caudal or brachial plexus block was performed. end-tidal concentration of sevoflurane was maintained at 2.5%. spontaneous respiratory was maintained. sevoflurane was stopped after the end of surgery. patients were randomly assigned to 2 groups: high concentration group (group hc, end-tidal concentration of sevoflurane when extubating \>=0.5%) and low concentration group (group lc, end-tidal concentration of sevoflurane when extubating \ = 0.5% were excluded. patients in group hc were extubated when any of the criteria was met: 1.the patient coughed or purposeful movement appeared 2.end-tidal concentration of sevoflurane decreased to 0.5%. a trained nurse (blind to groups) recorded paeds scores in pacu.

Eligibility criteria:
inclusion criteria: * age 2-7 years * asa i - ii * estimated surgery time \< 2 hours * sevoflurane induction and maintenance along with caudal block or axillary block exclusion criteria: * craniofacial anomalies * difficult exposure of the vocal cords * obesity * asthma * invalid caudal block or axillary block

Keywords: sevoflurane emergence delirium preschool
medical treatment in ectopic tubal pregnancy

Conditions: Ectopic Pregnancy

Summary: ectopic pregnancy (ep) is estimated to be responsible for approximately 20% of all pregnancy-related mortality and 46% early pregnancy mortality.1 hemodynamically stable women with ep are frequently managed with methotrexate (mtx) while multiple protocols like fixed multiple doses, single-dose as well as two-dose regimens have been in practice for treating ep, but no consensus exists regarding the optimum dosage regimen.

literature reports multiple dosage regimens of mtx to be associated with increased rates of side effects. single dose protocol has good compliance and fewer side effects but is linked with lower success rates in comparison to multiple dose protocols. a new treatment protocol involving "two-doses" of mtx for medical management of ep was introduced in 2007 but most of the research conducted so far has been retrospective in nature and limitations in study designs. no such study in recent years has been done in pakistan to compare the success and safety of single-dose and two-dose mtx protocols so this study was planned to compare the success rates and safety of two-doses of mtx versus single dose of mtx in tubal ep.

Eligibility criteria:
inclusion criteria: * diagnosis of tubal ectopic pregnancy. * pre-treatment beta-human chorionic gonadotrophin (β-hcg) level below 1500 miu/ml. * gestational sac with largest diameter as 4cm. * willing to take methotrexate treatment. * willing to follow up. exclusion criteria: * heterotrophic pregnancy * persistent tubal pregnancy * embryonic cardiac motion * suspected tubal rupture * past history of harmful effects of methotrexate treatment on organ functions.
ultrasound screening for developmental dysplasia of the hip in newborns

Conditions: Hip Dysplasia

Summary: the aim of the randomized controlled trial was to determine whether the addition of a general or of a selective ultrasound screening program resulted in more appropriate criteria for treatment and a reduced prevalence of late ddh compared with clinical examination alone.

this is a retrospective registration of a rct carried out in 1988-90, with a irb approved follow-up at skeletal maturity carried out in 2007-09. both the rct and the follow-up study were carried out in the same institution, by the same pi (prof. karen rosendahl) and her co-workers. detailed information is published in the following paper: rosendahl k, markestad t, lie rt. ultrasound screening for developmental dysplasia of the hip in the neonate: the effect on treatment rate and prevalence of late cases. pediatrics 1994;94:47-52. a sample of the initial rct was invited for a maturity review/follow-up at skeletal maturity. the follow-up at skeletal maturity is called: radiological indices of hip dysplasia and osteoarthritis at skeletal maturity in the bergen birth cohort. associations with neonatal hip dysplasia, childhood growth and genetic predisposition and is included in the approval by the regional ethical committee for medical and health research (no 3.2006.144). all participants of the follow-up study gave written informed consent according to the 1964 declaration of helsinki. the follow-up had the following main aims: 1) estimate the prevalence of radiologically defined hip dysplasia, femoroacetabular impingement and osteoarthritis assessed at skeletal maturity 2)report the frequency of 4 longitudinal dysplasia phenotypes based on sonographic assessments in the newborn and radiological assessments at skeletal maturity 3)investigate associations of dysplasia as defined in 1 and 2 above in univariate and multivariate models with clinically assessed hip joint mobility/joint hypermobility, weight, height and body mass index (bmi) at age 18/19 years, prepubertal weight, height and bmi trajectories using data from child health records, first degree family history of hip dysplasia with or without hip arthroplasty, perinatal factors, measures of oa including minimum joint space, acetabular depth ratio and reported hip pain 5) establish a genetic resource by obtaining and archiving salivary dna samples.

Eligibility criteria:
inclusion criteria: * all babies born at our institution during 1/1988-06/1990 exclusion criteria: * low birthweight \<1500 grams, severe malformations, death within first month

Keywords: hip dysplasia screening